Tapentadol Medical Valley 200 mg Norwegia - norweski - Statens legemiddelverk

tapentadol medical valley 200 mg

medical valley invest ab - tapentadoltartrat - depottablett - 200 mg

Venlazid 150 mg Norwegia - norweski - Statens legemiddelverk

venlazid 150 mg

medical valley invest ab - venlafaksinhydroklorid - depottablett - 150 mg

Venlazid 75 mg Norwegia - norweski - Statens legemiddelverk

venlazid 75 mg

medical valley invest ab - venlafaksinhydroklorid - depottablett - 75 mg

Venlazid 225 mg Norwegia - norweski - Statens legemiddelverk

venlazid 225 mg

medical valley invest ab - venlafaksinhydroklorid - depottablett - 225 mg

Kaletra Unia Europejska - norweski - EMA (European Medicines Agency)

kaletra

abbvie deutschland gmbh co. kg - lopinavir, ritonavir - hiv-infeksjoner - antivirals for systemic use, protease inhibitors - kaletra er angitt i kombinasjon med andre antiretrovirale legemidler til behandling av hiv-1-infiserte voksne, ungdommer og barn i alderen 14 og eldre. valg av kaletra til å behandle protease inhibitor opplevd hiv-1 infiserte pasienter bør være basert på individuelle viral motstand testing og behandling historie av pasienter.

Felimazole vet 2.5 mg Norwegia - norweski - Statens legemiddelverk

felimazole vet 2.5 mg

dechra limited - tiamazol - tablett, drasjert - 2.5 mg

Felimazole vet 1.25 mg Norwegia - norweski - Statens legemiddelverk

felimazole vet 1.25 mg

dechra limited - tiamazol - tablett, drasjert - 1.25 mg

Felimazole vet 5 mg Norwegia - norweski - Statens legemiddelverk

felimazole vet 5 mg

dechra limited - tiamazol - tablett, drasjert - 5 mg

Iclusig Unia Europejska - norweski - EMA (European Medicines Agency)

iclusig

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. se avsnitt 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Vidalta vet 15 mg Norwegia - norweski - Statens legemiddelverk

vidalta vet 15 mg

intervet international bv - 5831 an - karbimazol - depottablett - 15 mg